

This article printed from:



NeoStem Announces CEO to Lead Influential Science and Business Panel Discussion at Stem Cell Summit in Boston

NEW YORK--(BUSINESS WIRE)--Oct 2, 2007 - NeoStem, Inc. (AMEX:NBS), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announced that Company Chairman and Chief Executive Officer Robin L. Smith, M.D., will take part on a panel of experts to discuss important issues relating to policy, science and investment within the adult stem cell industry.

The Stem Cell Summit will gather the global community of industry leaders and stakeholders to learn, share ideas, search for solutions and focus on translating stem cell research from the laboratory to the bedside. Scheduled for October 2-3, 2007, the Summit is being planned by leading organizations in the bio-science field, including the Genetics Policy Institute, Harvard Stem Cell Institute and Burrill Life Science Media Group.

Panelists and speakers at the Summit will focus on issues and applications of stem cell science in the field of regenerative medicine, where research is being conducted to develop treatments for a wide range of diseases and conditions, including cancer, diabetes and neurological disorders.

Dr. Smith will take part in one of the Summit's "Conversations with Experts," a series of roundtables focusing on business, economic, political and therapeutic strategies. Topics to be discussed include NeoStem's experience and progress to advance collaborations between adult stem cell storage companies and physicians, hospitals and biopharma to realize the promise of adult stem cell innovation. Her panel discussion is scheduled for October 3, from 12 noon to 1:45 p.m. EST.

"I'm excited to meet with my colleagues in the global stem cell industry to share knowledge and strive to advance the state of this revolutionary field," said Dr. Smith. "Stem cell science and regenerative medicine have the potential to help millions of people suffering from various diseases and injuries, and gatherings such as the Stem Cell Summit can help us all increase our knowledge, contribute to the advancement of our industry and hopefully ultimately bring important new medical therapies to people everywhere."

Dr. Smith will also discuss NeoStem's newest initiatives, such as the Company's recently announced "Stem for Life" Foundation. Stem for Life is dedicated to heightening public awareness and knowledge of the benefits and the promise of utilizing adult stem cells to treat serious medical conditions in the burgeoning regenerative medicine industry. The foundation plans to lead a high-profile campaign directed at protecting the nation's first responders (fire, police, military) by assisting them in having collected and stored their own stem cells for potential recovery following national emergencies and war-related injuries.

Although adult stem cell therapies are generally not standard-of-care, NeoStem and many lending experts in the field believe medicine is on the threshold of a plethora of such new therapies. There are currently more than 700 adult stem cell clinical trials listed by the National Institutes of Health. These include studies in a myriad of life-threatening diseases including several types of cancer, heart disease, diabetes, lupus as well as regenerative wound and transplant therapies.

The Stem Cell Summit is scheduled to take place at the Hynes Auditorium in Boston, MA. For more information visit <http://www.thestemcellsummit.com/index.htm#>.

About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one's future health.

The Company's business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: www.neostem.com.

For other information and resources about the Company, visit www.CFSG1.com or www.tribgy-capital.com/tcp/neostem/quote.html.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.

Contact

NeoStem, Inc.

Robin Smith, Chief Executive Officer, 212-584-4180

rsmith@neostem.com

www.neostem.com

or

Consulting for Strategic Growth 1

Stanley Wunderlich/Daniel Stepanek, 800-625-2236

Fax: 212-337-8089

<http://www.cfsg1.com>

or

Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com